Combined use of bendamustine, doxorubicin and bortezomib for...

Details Combined use of bendamustine, doxorubicin and bortezomib for... Combined use of bendamustine, doxorubicin and bortezomib for...

A - Human Necessities

61

K

A61K 31/69 (2006.01) A61K 31/4184 (2006.01) A61K 31/704 (2006.01) A61P 35/00 (2006.01)

Patent

CA 2741276

Methods for treating multiple myeloma by administering a combination of a proteasome inhibitor, bendamustine and doxorubicin are described.

La présente invention concerne des procédés pour traiter le myélome multiple par administration dune combinaison dun inhibiteur de protéasome, de bendamustine et de doxorubicine.

Affiliated with

Also associated with

Rating

Combined use of bendamustine, doxorubicin and bortezomib for... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combined use of bendamustine, doxorubicin and bortezomib for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined use of bendamustine, doxorubicin and bortezomib for... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1520844